JPH0812572A - Therapeutic agent for dermatomycosis - Google Patents
Therapeutic agent for dermatomycosisInfo
- Publication number
- JPH0812572A JPH0812572A JP17159494A JP17159494A JPH0812572A JP H0812572 A JPH0812572 A JP H0812572A JP 17159494 A JP17159494 A JP 17159494A JP 17159494 A JP17159494 A JP 17159494A JP H0812572 A JPH0812572 A JP H0812572A
- Authority
- JP
- Japan
- Prior art keywords
- surfactant
- therapeutic agent
- dermatomycosis
- nonionic surfactant
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 33
- 208000007163 Dermatomycoses Diseases 0.000 title claims abstract description 27
- 201000003929 dermatomycosis Diseases 0.000 title claims abstract description 27
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 34
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 27
- -1 polyoxyethylene Polymers 0.000 claims abstract description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 11
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims abstract description 10
- 239000004471 Glycine Substances 0.000 claims abstract description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 8
- 241000233866 Fungi Species 0.000 claims abstract description 7
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 7
- 150000005215 alkyl ethers Chemical class 0.000 claims abstract description 6
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 26
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 239000002280 amphoteric surfactant Substances 0.000 abstract description 5
- 241000223238 Trichophyton Species 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 11
- 201000004647 tinea pedis Diseases 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 6
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 208000024386 fungal infectious disease Diseases 0.000 description 3
- 230000002070 germicidal effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000004287 Dehydroacetic acid Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 2
- 229940061632 dehydroacetic acid Drugs 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 description 2
- 150000002462 imidazolines Chemical class 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 2
- 229960004880 tolnaftate Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- QVJAHWMTSXACSQ-UHFFFAOYSA-N 2-amino-3-methylbutan-2-ol Chemical compound CC(C)C(C)(N)O QVJAHWMTSXACSQ-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、皮膚真菌症治療剤に関
し、特に、水虫治療薬として白癬菌に冒された患部例え
ば足を当該液剤の水虫治療薬に浸し足浴させることによ
り、従来の治療法では考えられない程、短期間で、か
つ、非常に優れた効果的な方法で、患部を清浄な状態に
回復させる治療を行うことができる皮膚真菌症治療剤に
関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic agent for dermatomycosis, and in particular, it is used as a therapeutic agent for athlete's foot, by treating the affected area such as foot with a therapeutic agent for athlete's foot, which is a conventional solution, by a foot bath. The present invention relates to a therapeutic agent for dermatomycosis capable of performing treatment for recovering an affected area to a clean state in a short period of time, which is unthinkable by law, and by a very excellent and effective method.
【０００２】[0002]
【従来の技術】白癬症、ガンジダ症等の皮膚真菌症は、
長期間に渡る治療を行ってもなかなか良くならず、その
為に困っている人が多くいるのが現状である。2. Description of the Related Art Dermatomycosis such as tinea and gandidiasis are
The current situation is that even after long-term treatment, the treatment does not improve, and many people are in trouble.
【０００３】皮膚真菌症治療剤として、各種のものが提
案されており、硝酸オコモナゾール、２−ヘキシルオキ
シベンズアミド、デヒドロ酢酸、クロトリマゾール、ト
ルナフテート、パクチオン等を有効成分とした外用もし
くは内服薬が提案されている（例えば、特開平４−３２
１６２６号公報、特公昭５３−７４８７号公報、特開昭
５７−５８６２５号公報、特開平２−２９２２１９号公
報）。Various agents have been proposed as therapeutic agents for dermatomycosis, and external or internal medicines containing okomonazole nitrate, 2-hexyloxybenzamide, dehydroacetic acid, clotrimazole, tolnaftate, paction and the like as active ingredients have been proposed. (For example, Japanese Patent Laid-Open No. 4-32
1626, JP-B-53-7487, JP-A-57-58625, and JP-A-2-292219).
【０００４】当該皮膚真菌症治療剤には、界面活性剤と
当該有効成分とを組合わせた形態で皮膚真菌症治療剤を
構成したものも各種提案されており、例えば、特開昭５
７−５８６２５号公報には、デヒドロ酢酸とトリメチル
型またはベンジル型界面活性剤とからなる皮膚真菌症治
療剤が、また、特開昭６３−２５８４１３号公報には、
トルナフテートと陰イオン性（アニオン性）界面活性剤
等とよりなる真菌症治療剤等が提案されている。As the dermatomycosis therapeutic agent, various types of dermatomycosis therapeutic agent constituted in the form of a combination of a surfactant and the active ingredient have been proposed.
7-58625 discloses a therapeutic agent for dermatomycosis comprising dehydroacetic acid and a trimethyl type or benzyl type surfactant, and JP-A-63-258413 discloses
A therapeutic agent for fungal diseases comprising tolnaftate and an anionic (anionic) surfactant has been proposed.
【０００５】一方、界面活性剤が水虫治療薬として有用
であることも以前から知られており、例えば、特開昭５
８−２１３７１５号公報には、特定のアルファオレフイ
ン系陰イオン性界面活性剤を含有した水虫治療薬が提案
されており、また、特開昭６３−２３０６４０号公報に
は、陰イオン性（アニオン性）界面活性剤と分子内に窒
素原子を有しない非イオン性界面活性剤とを有効成分と
した水虫治療効果を奏する皮膚外用製剤が提案されてい
る。On the other hand, it has been known for a long time that a surfactant is useful as a remedy for athlete's foot, for example, Japanese Unexamined Patent Publication No. Sho 5
8-213715 discloses a remedy for athlete's foot containing a specific alpha olefin-type anionic surfactant, and JP-A-63-230640 discloses anionic (anionic) agents. ) A skin external preparation having a therapeutic effect on athlete's foot, which comprises a surfactant and a nonionic surfactant having no nitrogen atom in the molecule as active ingredients, has been proposed.
【０００６】[0006]
【発明が解決しようとする課題】本発明の目的は、かか
る従来技術に鑑み、皮膚真菌症治療剤として有用で、特
に、白癬菌などの真菌に冒された患部を足浴させること
により、従来の治療法では考えられない程、短期間で、
かつ、非常に優れた効果的な方法で、患部を清浄な状態
に回復させる治療を行うことができる皮膚真菌症治療剤
を提供することを目的としたものである。本発明の前記
ならびにそのほかの目的と新規な特徴は、本明細書の記
述からあきらかになるであろう。SUMMARY OF THE INVENTION In view of such prior art, the object of the present invention is useful as a therapeutic agent for dermatomycosis, and in particular, by foot bathing an affected area affected by fungi such as Trichophyton. In a short period of time, which is unthinkable with treatment methods,
Moreover, it is an object of the present invention to provide a therapeutic agent for dermatomycosis, which can treat the affected area to a clean state by a very excellent and effective method. The above and other objects and novel characteristics of the present invention will be apparent from the description of the present specification.
【０００７】[0007]
【課題を解決するための手段】本発明は、（Ａ）陽イオ
ン性界面活性剤と（Ｂ）両性イオン界面活性剤と（Ｃ）
非イオン性界面活性剤とからなることを特徴とする皮膚
真菌症治療剤に係るもので、好ましい実施態様として、
前記（Ａ）陽イオン性界面活性剤が第四級アンモニウム
塩特に塩化ベンザルコニウムよりなる陽イオン性界面活
性剤で、（Ｂ）両性イオン界面活性剤がアミノカルボン
酸またはその塩特に長鎖アルキルジ（アミノエチル）グ
リシンまたはその塩よりなる両性イオン界面活性剤で、
また、（Ｃ）非イオン性界面活性剤がエーテル型非イオ
ン性界面活性剤特にポリオキシエチレンアルキルエーテ
ル就中ポリオキシエチレンラウリルエーテルよりなる非
イオン性界面活性剤であることを特徴とする皮膚真菌症
治療剤に係るものである。The present invention provides (A) a cationic surfactant, (B) a zwitterionic surfactant, and (C).
The present invention relates to a therapeutic agent for dermatomycosis, which comprises a nonionic surfactant, and as a preferred embodiment,
The (A) cationic surfactant is a cationic surfactant composed of a quaternary ammonium salt, particularly benzalkonium chloride, and (B) the zwitterionic surfactant is an aminocarboxylic acid or a salt thereof, particularly a long-chain alkyldiamine. A zwitterionic surfactant consisting of (aminoethyl) glycine or a salt thereof,
Further, the skin fungus characterized in that (C) the nonionic surfactant is an ether type nonionic surfactant, in particular a polyoxyethylene alkyl ether, especially polyoxyethylene lauryl ether. The present invention relates to therapeutic agents for diseases.
【０００８】本発明において使用される（Ａ）陽イオン
性界面活性剤とは、水溶液において解離し界面活性を示
す部分がカチオンとなる界面活性剤をいう。当該（Ａ）
陽イオン性界面活性剤の例には、例えば、次の物質より
なる陽イオン性界面活性剤を挙げることができる。第四
級アンモニウム塩例えば、 （１）一般式［ＲＮ（ＣＨ3）2ＣＨ2Ｃ6Ｈ5］+Ｘ-（但
し、式中のＲはアルキル基、Ｘはハロゲン原子）で表さ
れる塩化ベンザルコニウム （２）一般式ＲＮ+（ＣＨ3）3・Ｘ-（但し、式中のＲは
アルキル基、Ｘはハロゲン原子）で表されるアルキルト
リメチルアンモニウム塩 （３）一般式［ＲＮ（ＣＨ3）2ＣＨ2ＣＨ2ＯＨ］+ＯＨ-
（但し、式中のＲはアルキル基）で表されるアルキルア
ミノエタノールThe cationic surfactant (A) used in the present invention is a surfactant whose dissociation in an aqueous solution and which exhibits surface activity becomes a cation. The (A)
Examples of cationic surfactants include, for example, cationic surfactants composed of the following substances. Quaternary ammonium salt, for example, (1) Chloride represented by the general formula [RN (CH 3 ) 2 CH 2 C 6 H 5 ] + X − (wherein R is an alkyl group and X is a halogen atom). Benzalkonium (2) Alkyltrimethylammonium salt represented by the general formula RN + (CH 3 ) 3 · X − (where R is an alkyl group and X is a halogen atom) (3) The general formula [RN ( CH 3) 2 CH 2 CH 2 OH] + OH -
(However, R in the formula is an alkyl group)
【０００９】上記（１）の一般式中のアルキル基Ｒの例
としては、炭素数が８〜２０のアルキル基例えばオクチ
ル、ノニル、デシル、ウンデシル、ラウリル、トリデシ
ル、ミリスチル、ペンタデシル、セチル、ヘプタデシ
ル、ステアリルが挙げられ、また、ハロゲン原子Ｘの例
としては、塩素原子、臭素原子が挙げられる。当該一般
式で表される塩化ベンザルコニウムの例としては、テト
ラデシルジメチルベンジルアンモニウムクロライド、オ
クタデシルジメチルベンジルアンモニウムクロライド、
その他椰子アルキルジメチルベンジルアンモニウムクロ
ライド等が挙げられる。Examples of the alkyl group R in the general formula (1) include alkyl groups having 8 to 20 carbon atoms such as octyl, nonyl, decyl, undecyl, lauryl, tridecyl, myristyl, pentadecyl, cetyl, heptadecyl, Examples thereof include stearyl, and examples of the halogen atom X include a chlorine atom and a bromine atom. Examples of benzalkonium chloride represented by the general formula include tetradecyldimethylbenzylammonium chloride, octadecyldimethylbenzylammonium chloride,
Other examples include palm alkyl dimethyl benzyl ammonium chloride.
【００１０】上記（２）の一般式中のアルキル基Ｒの例
としては、前記と同様の炭素数が８〜２０のアルキル基
が挙げられ、また、ハロゲン原子Ｘの例としては、塩素
原子、臭素原子が挙げられる。当該アルキルトリメチル
アンモニウム塩の例としては、ドデシルトリメチルアン
モニウムクロライド、ヘキサデシルトリメチルアンモニ
ウムクロライド、オクタデシルトリメチルアンモニウム
クロライド、その他椰子アルキルトリメチルアンモニウ
ムクロライド等が挙げられる。Examples of the alkyl group R in the general formula (2) above include the same alkyl groups having 8 to 20 carbon atoms as described above, and examples of the halogen atom X include a chlorine atom, A bromine atom is mentioned. Examples of the alkyltrimethylammonium salt include dodecyltrimethylammonium chloride, hexadecyltrimethylammonium chloride, octadecyltrimethylammonium chloride, and palm alkyltrimethylammonium chloride.
【００１１】上記（３）の一般式で表されるアルキルア
ミノエタノールの例としては、トリメチルアミノエタノ
ール等が挙げられる。Examples of the alkylaminoethanol represented by the above general formula (3) include trimethylaminoethanol and the like.
【００１２】本発明においては、上記（Ａ）陽イオン性
界面活性剤として水溶液において解離し界面活性を示す
部分がカチオンとなる各種の陽イオン性界面活性剤を使
用することができるが、皮膚真菌症に対する治療効果に
優れ、また、当該（Ａ）陽イオン性界面活性剤と（Ｂ）
両性イオン性界面活性剤と（Ｃ）非イオン性界面活性剤
との組合わせから、第四級アンモニウム塩として、特
に、前記（１）一般式［ＲＮ（ＣＨ3）2ＣＨ2Ｃ6Ｈ5］+
Ｘ-（但し、式中のＲは前記に同じ、Ｘは、前記に同
じ）で表される塩化ベンザルコニウムを使用することが
好ましい。In the present invention, as the above-mentioned (A) cationic surfactant, various cationic surfactants which dissociate in an aqueous solution and show a surface-active portion as a cation can be used. Is excellent in the therapeutic effect on the infectious diseases, and the (A) cationic surfactant and (B)
From the combination of a zwitterionic surfactant and a nonionic surfactant (C), as a quaternary ammonium salt, in particular, the above formula (1) [RN (CH 3 ) 2 CH 2 C 6 H 5 ] +
It is preferable to use benzalkonium chloride represented by X − (wherein R is the same as above and X is the same as above).
【００１３】本発明において使用される（Ｂ）両性イオ
ン界面活性剤とは、水溶液において解離し界面活性を示
す部分が例えばアニオン活性とカチオン活性というよう
に２種ある界面活性剤をいい、カルボン酸型、硫酸エス
テル型、スルホン酸型、リン酸エステル型等各種の両性
界面活性剤を使用することができる。当該（Ｂ）両性イ
オン界面活性剤の例には、例えば、次の物質よりなる両
性界面活性剤を挙げることができる。The (B) zwitterionic surfactant used in the present invention refers to a surfactant having two types of moieties that dissociate in an aqueous solution and exhibit surface activity, such as anionic activity and cationic activity. It is possible to use various amphoteric surfactants such as type, sulfuric acid ester type, sulfonic acid type and phosphoric acid ester type. Examples of the (B) zwitterionic surfactant include, for example, an amphoteric surfactant made of the following substances.
【００１４】[0014]
【式１】 を有するアミノカルボン酸またはその塩(Equation 1) Having aminocarboxylic acid or salt thereof
【００１５】[0015]
【式２】 を有するカルボキシベタインもしくはスルホベタイン(Equation 2) With carboxybetaine or sulfobetaine
【００１６】[0016]
【式３】 を有するイミダゾリン誘導体(Equation 3) Having imidazoline derivative
【００１７】上記式１のアミノカルボン酸またはその塩
型両性イオン界面活性剤の例としては、一般式 Ｒ−Ｎ
Ｈ−（ＣＨ2）nＣＯＯＭ（但し、Ｒはアルキル基、ｎは
整数、Ｍは金属または水素原子）で示されるアミノカル
ボン酸またはその金属塩を主成分とするもの等が挙げら
れ、当該アルキル基の例としては、炭素数１２〜１８の
アルキル基例えばラウリル、トリデシル、ミリスチル、
ペンタデシル、セチル、ヘプタデシル、ステアリルが挙
げられ、また、ｎは、通常、１〜２の整数である。上記
アミノカルボン酸またはその塩の具体例としては、長鎖
アルキルジ（アミノエチル）グリシンまたはそのナトリ
ウム塩等が挙げられる。当該アミノカルボン酸またはそ
の塩型（グリシン型）の両性界面活性剤として、日本油
脂社製の商品名アノンＬＧ等を使用することができる。Examples of the aminocarboxylic acid of the above formula 1 or its salt type zwitterionic surfactant include those represented by the general formula RN
H- (CH 2 ) n COOM (wherein R is an alkyl group, n is an integer, M is a metal or a hydrogen atom), and the like having an aminocarboxylic acid or a metal salt thereof as a main component, and the like are mentioned. Examples of the group include alkyl groups having 12 to 18 carbon atoms such as lauryl, tridecyl, myristyl,
Pentadecyl, cetyl, heptadecyl and stearyl are mentioned, and n is usually an integer of 1-2. Specific examples of the aminocarboxylic acid or a salt thereof include long-chain alkyldi (aminoethyl) glycine or a sodium salt thereof. As the aminocarboxylic acid or its salt-type (glycine-type) amphoteric surfactant, Anon LG or the like manufactured by NOF CORPORATION can be used.
【００１８】上記式２のカルボキシベタインもしくはス
ルホベタイン型両性イオン界面活性剤の例としては、一
般式 （Ｒ）3−Ｎ−（ＣＨ2）nＣＯＯＨ（但し、Ｒは
同一もしくは相異なるアルキル基、ｎは整数）で示され
る基本骨格を有するカルボキシベタイン型界面活性剤が
挙げられ、当該アルキル基の例としては、メチル基等の
低級アルキル基、前記と同様の炭素数１２〜１８のアル
キル基が例示され、また、ｎは、通常、１〜２の整数で
ある。上記カルボキシベタインベタイン型両性イオン界
面活性剤としては、Ｇｏｌｄｓｃｈｍｉｄｉｔ社のＴＥ
ＧＯ−Ｂｅｔａｉｎｅ等を使用することができる。Examples of the carboxybetaine- or sulfobetaine-type zwitterionic surfactants of the above formula 2 are represented by the general formula (R) 3 -N- (CH 2 ) n COOH (where R is the same or different alkyl group, A carboxybetaine type surfactant having a basic skeleton represented by (n is an integer) is exemplified, and examples of the alkyl group include a lower alkyl group such as a methyl group and an alkyl group having 12 to 18 carbon atoms similar to the above. It is exemplified, and n is usually an integer of 1 to 2. The carboxybetaine betaine-type zwitterionic surfactant is TE of Goldschmidit.
GO-Betaine or the like can be used.
【００１９】上記式３のイミダゾリン誘導体の例として
は、２−アルキルーＮ−カルボキシメチルーＮーヒドロ
キシエチルイニダゾリニウムベタイン等が挙げられる。Examples of the imidazoline derivative of the above formula 3 include 2-alkyl-N-carboxymethyl-N-hydroxyethylinidazolinium betaine.
【００２０】本発明においては、（Ｂ）両性イオン界面
活性剤として前記したような各種の両性イオン界面活性
剤を使用することができるが、皮膚真菌症に対する治療
効果に優れ、皮膚に対する刺激が特に強くなく、また、
当該（Ｂ）両性イオン界面活性剤と（Ａ）陽イオン性界
面活性剤と（Ｃ）非イオン性界面活性剤との組合わせか
ら、アミノカルボン酸またはその塩、特に、長鎖アルキ
ルジ（アミノエチル）グリシンナトリウム塩、就中、ラ
ウリルジ（アミノエチル）グリシンナトリウムを使用す
ることが好ましい。In the present invention, various kinds of zwitterionic surfactants as described above can be used as the (B) zwitterionic surfactant, but they are excellent in the therapeutic effect on dermatomycosis and the irritation to the skin is particularly excellent. Not strong again
From the combination of the (B) zwitterionic surfactant, (A) cationic surfactant, and (C) nonionic surfactant, aminocarboxylic acid or a salt thereof, particularly long-chain alkyldi (aminoethyl) ) It is preferred to use glycine sodium salt, especially sodium lauryl di (aminoethyl) glycine.
【００２１】本発明において使用される（Ｃ）非イオン
性界面活性剤とは、水溶液においてイオンに解離しない
界面活性剤をいう。当該（Ｃ）非イオン性界面活性剤の
例には、例えば、次の物質を挙げることができる。 （Ｃ−１）エーテル型非イオン性界面活性剤 当該エーテル型非イオン性界面活性剤の例には、ポリオ
キシエチレンアルキルエーテル、ポリオキシエチレンフ
ェニルエーテルがある。 （Ｃ−２）エーテルエステル型非イオン性界面活性剤 当該エーテルエステル型非イオン性界面活性剤の例に
は、ポリオキシエチレンソルビタン脂肪酸エステル、ポ
リオキシエチレンソルビタングリセリル脂肪酸エステ
ル、ポリオキシエチレンプロピレングリコールグリセリ
ル脂肪酸エステル、ポリオキシエチレンソルビトール脂
肪酸エステル、天然油脂およびロウ類のポリオキシエチ
レン誘導体がある。The nonionic surfactant (C) used in the present invention is a surfactant which does not dissociate into ions in an aqueous solution. Examples of the nonionic surfactant (C) include the following substances. (C-1) Ether Type Nonionic Surfactant Examples of the ether type nonionic surfactant include polyoxyethylene alkyl ether and polyoxyethylene phenyl ether. (C-2) Ether Ester Nonionic Surfactant Examples of the ether ester nonionic surfactant include polyoxyethylene sorbitan fatty acid ester, polyoxyethylene sorbitan glyceryl fatty acid ester, polyoxyethylene propylene glycol glyceryl. There are polyoxyethylene derivatives of fatty acid esters, polyoxyethylene sorbitol fatty acid esters, natural fats and oils and waxes.
【００２２】上記（Ｃ−１）エーテル型非イオン性界面
活性剤および（Ｃ−２）エーテルエステル型非イオン性
界面活性剤におけるアルキル基の例としては、オクチ
ル、ノニル、デシル、ウンデシル、ラウリル、トリデシ
ル、ミリスチル、ペンタデシル、セチル、ヘプタデシ
ル、ステアリルが挙げられる。Examples of the alkyl group in the above (C-1) ether type nonionic surfactant and (C-2) ether ester type nonionic surfactant include octyl, nonyl, decyl, undecyl, lauryl, Examples include tridecyl, myristyl, pentadecyl, cetyl, heptadecyl and stearyl.
【００２３】本発明においては、（Ｃ）非イオン性界面
活性剤として前記したような各種の非イオン性界面活性
剤を使用することができるが、皮膚真菌症に対する治療
効果に優れ、また、当該（Ｃ）非イオン性界面活性剤と
（Ａ）陽イオン性界面活性剤と（Ｂ）両性イオン界面活
性剤との組合わせから、（Ｃ−１）エーテル型非イオン
性界面活性剤、特に、次の一般式で表されるポリオキシ
エチレンアルキルエーテル、特に、ポリオキシエチレン
ラウリルエーテルを使用することが好ましい。 一般式 ＲＯ（Ｃ2Ｈ4）nＨ （但し、Ｒはアルキル基、ｎは整数） 当該アルキル基の例としては、炭素数８〜１８のアルキ
ル基が例示され、ｎは６以下の整数であることが好まし
い。アルキル基の具体例は、オクチル、ノニル、デシ
ル、ウンデシル、ラウリル、トリデシル、ミリスチル、
ペンタデシル、セチル、ヘプタデシル、ステアリルが挙
げられる。In the present invention, various nonionic surfactants as described above can be used as the nonionic surfactant (C), but they are excellent in the therapeutic effect on dermatomycosis, and From the combination of (C) a nonionic surfactant, (A) a cationic surfactant and (B) a zwitterionic surfactant, (C-1) an ether type nonionic surfactant, in particular, It is preferable to use a polyoxyethylene alkyl ether represented by the following general formula, particularly a polyoxyethylene lauryl ether. Formula RO (C 2 H 4) n H ( where, R represents an alkyl radical, n is an integer) Examples of such alkyl groups are exemplified by alkyl group having 8 to 18 carbon atoms, n represents 6 or less integer Preferably there is. Specific examples of the alkyl group include octyl, nonyl, decyl, undecyl, lauryl, tridecyl, myristyl,
Examples include pentadecyl, cetyl, heptadecyl, and stearyl.
【００２４】本発明においては、（Ａ）陽イオン性界面
活性剤と（Ｂ）両性イオン界面活性剤と（Ｃ）非イオン
性界面活性剤はいずれも必須であり、これら界面活性剤
の混合物により皮膚真菌症治療剤が構成される。前記の
ように、好ましくは、当該（Ａ）陽イオン性界面活性剤
として第四級アンモニウム塩特に前記式で表わされる塩
化ベンザルコニウムを使用し、（Ｂ）両性イオン界面活
性剤として前記式で表わされるアミノカルボン酸または
その塩特に、長鎖アルキルジ（アミノエチル）グリシン
またはその金属塩特にラウリルジ（アミノエチル）グリ
シンナトリウムを使用し、さらに、これら界面活性剤に
加えて、（Ｃ）非イオン性界面活性剤として前記式で表
わされるポリオキシエチレンアルキルエーテル就中ポリ
オキシエチレンラウリルエーテルを使用して皮膚真菌症
治療剤を構成する。In the present invention, all of (A) the cationic surfactant, (B) the zwitterionic surfactant, and (C) the nonionic surfactant are essential, and the mixture of these surfactants may be used. A therapeutic agent for dermatomycosis is constituted. As described above, it is preferable to use the quaternary ammonium salt as the (A) cationic surfactant, particularly benzalkonium chloride represented by the above formula, and (B) use the above formula as the zwitterionic surfactant. Aminocarboxylic acids or salts thereof represented, in particular long-chain alkyldi (aminoethyl) glycine or metal salts thereof, in particular sodium lauryldi (aminoethyl) glycine, are used, and in addition to these surfactants, (C) nonionic The polyoxyethylene alkyl ether represented by the above formula, especially polyoxyethylene lauryl ether, is used as a surfactant to form a therapeutic agent for dermatomycosis.
【００２５】本発明の治療剤における（Ａ）陽イオン性
界面活性剤と（Ｂ）両性イオン界面活性剤と（Ｃ）非イ
オン性界面活性剤との混合比率は、任意に選択可能であ
るが、（Ａ）陽イオン性界面活性剤を１とすれば、
（Ｂ）両性イオン界面活性剤は０．５〜１．５であり、
また、（Ｃ）非イオン性界面活性剤は２〜６である。す
なわち、その好ましい混合比率は、（Ａ）陽イオン性界
面活性剤：（Ｂ）両性イオン界面活性剤：（Ｃ）非イオ
ン性界面活性剤＝１：０．５〜１．５：２〜６である。 （Ｂ）両性イオン界面活性剤の混合比率が、（Ａ）陽イ
オン性界面活性剤１に対して０．５未満では、皮膚に対
する浸透性が弱くなり、真菌に対する殺菌力も弱くな
り、本発明所望の真菌症治療効果が不充分となる。一
方、１．５を超えて配合しても、効果が飽和するし、当
該（Ｂ）両性イオン界面活性剤と（Ａ）陽イオン界面活
性剤と（Ｃ）非イオン性界面活性剤との間のバランスが
とれず、本発明所望の真菌症治療効果が不充分となる。 （Ｃ）非イオン性界面活性剤の混合比率が、（Ａ）陽イ
オン性界面活性剤１に対して２未満では、皮膚に付着す
る真菌に対する洗浄殺菌作用が弱くなり、本発明所望の
真菌症治療効果が不充分となる。一方、６を超えて配合
しても、効果が飽和するし、当該（Ｃ）非イオン性界面
活性剤と（Ａ）陽イオン界面活性剤と（Ｂ）両性イオン
性界面活性剤との間のバランスがとれず、本発明所望の
真菌症治療効果が不充分となる。In the therapeutic agent of the present invention, the mixing ratio of (A) cationic surfactant, (B) zwitterionic surfactant and (C) nonionic surfactant can be arbitrarily selected. , (A) if the cationic surfactant is 1,
(B) the zwitterionic surfactant is 0.5 to 1.5,
Moreover, (C) nonionic surfactant is 2-6. That is, the preferable mixing ratio is (A) cationic surfactant: (B) zwitterionic surfactant: (C) nonionic surfactant = 1: 0.5 to 1.5: 2 to 6 Is. If the mixing ratio of the (B) zwitterionic surfactant is less than 0.5 with respect to (A) the cationic surfactant 1, the permeability to the skin will be weak and the bactericidal activity against fungi will be weak, and the present invention is desired. The mycosis treatment effect of is insufficient. On the other hand, even if the amount is more than 1.5, the effect is saturated, and the effect between the (B) zwitterionic surfactant, (A) cationic surfactant and (C) nonionic surfactant is increased. However, the effect of treating mycosis desired by the present invention is insufficient. When the mixing ratio of the nonionic surfactant (C) is less than 2 relative to 1 of the cationic surfactant (A), the bactericidal action against the fungus adhering to the skin is weakened and the fungal disease desired by the present invention is obtained. The therapeutic effect becomes insufficient. On the other hand, even if the amount exceeds 6, the effect is saturated, and the effect between the (C) nonionic surfactant, (A) cationic surfactant and (B) zwitterionic surfactant is increased. It is not balanced, and the desired fungal disease treatment effect of the present invention is insufficient.
【００２６】本発明の治療剤には、香料、キレート剤等
の各種添加助剤等を適宜必要に応じて配合することがで
きる。The therapeutic agent of the present invention may contain various additives such as fragrances and chelating agents, if necessary.
【００２７】本発明の治療剤を皮膚真菌症の患部に適用
する際には、例えば、水またはお湯にて希釈し、患部を
浸せばよい。塗布等の手段によってもよい。When the therapeutic agent of the present invention is applied to an affected area of dermatomycosis, it may be diluted with, for example, water or hot water, and the affected area may be dipped. Means such as coating may be used.
【００２８】陽イオン性界面活性剤と両性イオン界面活
性剤と非イオン性界面活性剤との混合物は、外用殺菌消
毒剤として使用されており、その急性毒性には問題がな
いことが確認されている。因みに、当該外用殺菌消毒剤
の毒性に関するデータを次に示す。尚、当該試験に供し
た外用殺菌消毒剤は、その主成分が、塩化ベンザルコニ
ウム（陽イオン性界面活性剤）４．０％、日本油脂社製
の商品名アノンＬＧ（両性イオン界面活性剤）１０．０
％及びポリオキシエチレンラウリルエーテル（非イオン
性界面活性剤）１６．０％よりなっている。 毒性 検体 致死量 外用殺菌消毒剤 １．２ｍｌ／ｋｇ１０Ｗ／Ｖ％塩化ベンザルコニウム液 ０．１６ｇ／ｋｇ ｄｄ系のマウス（雄）を用い腹腔内注射によって致死量
を求めた。上記から、毒性は、水虫治療薬として用いら
れることがある毒性の低い塩化ベンザルコニウム液の約
８分の１であることが判る。A mixture of a cationic surfactant, a zwitterionic surfactant and a nonionic surfactant is used as an external germicidal disinfectant, and it has been confirmed that its acute toxicity has no problem. There is. By the way, the data on the toxicity of the external sterilizer are shown below. The external germicidal disinfectant used in the test was composed mainly of benzalkonium chloride (cationic surfactant) 4.0%, manufactured by NOF Corporation, Anon LG (zwitterionic surfactant). ) 10.0
% And polyoxyethylene lauryl ether (nonionic surfactant) 16.0%. Toxic sample Lethal dose External germicidal disinfectant 1.2 ml / kg 10 W / V% benzalkonium chloride solution 0.16 g / kg Lethal dose was determined by intraperitoneal injection using a dd mouse (male). From the above, it can be seen that the toxicity is about one-eighth of the less toxic benzalkonium chloride solution which may be used as a remedy for athlete's foot.
【００２９】本発明の真菌症治療剤は、亜鉛華、吉草酸
ベタメタゾリン、吉草酸酢酸プレドニゾンベタメタゾリ
ン等を有効成分とする皮膚疾患治療剤を併用することが
できる。The agent for treating mycosis of the present invention may be used in combination with an agent for treating skin diseases containing zinc oxide, betamethazoline valerate, prednisone acetate valerate betamethazoline and the like as active ingredients.
【００３０】[0030]
【実施例】以下、本発明の実施例を示す。 実施例１ 塩化ベンザルコニウム ０．０２ｗｔ％ ラウリルジ（アミノエチル）グリシンナトリウム ０．０１５ｗｔ％ ポリオキシエチレンラウリルエーテル ０．０８ｗｔ％ よりなる希釈濃度の水溶液を用い、表存性水虫趾間型の
患部を有する患者に適用し、その足を１日当り１５分間
毎日足浴させたところ、約１週間で皮膚が元の状態に戻
った。上記溶液を用い、同様の症状の患者に適用したと
ころ、他７例の臨床結果においても、同様に約１週間で
皮膚が元の状態に戻り、患者によっては、約３日間で皮
膚が元の状態に戻り完治した。また、上記溶液を深存性
水虫患者に適用し、１日当り１５分間毎日足浴させたと
ころ、約１カ月で皮膚が元の状態に戻った。EXAMPLES Examples of the present invention will be shown below. Example 1 Benzalkonium chloride 0.02 wt% Sodium lauryl di (aminoethyl) glycine 0.015 wt% Polyoxyethylene lauryl ether 0.08 wt% An aqueous solution with a dilute concentration of 0.08 wt% was used, and there was a superficial athlete's foot toe-shaped lesion. When applied to a patient and the foot was bathed daily for 15 minutes per day, the skin returned to its original state in about 1 week. When the above solution was used and applied to patients with similar symptoms, the clinical results of the other 7 cases also returned the skin to its original state in about 1 week, and depending on the patient, the skin was recovered in about 3 days. It returned to the state and healed completely. Further, when the above solution was applied to a deep-seated athlete's foot patient and a foot bath was performed daily for 15 minutes per day, the skin returned to its original state in about 1 month.
【００３１】実施例２ 塩化ベンザルコニウム ０．０２ｗｔ％ ラウリルジ（アミノエチル）グリシンナトリウム ０．０１５ｗｔ％ ポリオキシエチレンラウリルエーテル ０．０８ｗｔ％ よりなる希釈濃度の水溶液を用い、表存性水虫角化型の
患部を有する患者に適用した。この患者は、表存性水虫
角化型の患者で皮膚が長期にわたって水虫に冒されてお
り、こじれた皮膚の状態にあった。１日当り３０分間毎
日足浴させた後、亜鉛華軟膏を塗布させたところ、痒が
すぐにとれた。この治療法を１０日間継続させたとこ
ろ、皮膚は清浄な状態に回復し、完治した。Example 2 Benzalkonium chloride 0.02 wt% Sodium lauryl di (aminoethyl) glycine 0.015 wt% Polyoxyethylene lauryl ether 0.08 wt% Using an aqueous solution of a dilute concentration, a superficial athlete's foot keratinized type was used. The present invention was applied to patients with affected areas. This patient was a superficial athlete's foot keratosis type patient whose skin had been affected by athlete's foot for a long period of time and was in a condition of kinked skin. After daily foot bathing for 30 minutes per day, zinc oxide ointment was applied, and the pruritus was immediately removed. When this treatment was continued for 10 days, the skin was restored to a clean state and healed completely.
【００３２】[0032]
【発明の効果】以上本発明によれば、皮膚真菌症治療剤
として有用で、特に、白癬菌などの真菌に冒された患部
を足浴させることにより、従来の治療法では考えられな
い程、短期間で、かつ、非常に優れた効果的な方法で、
患部を清浄な状態に回復させる治療を行うことができる
皮膚真菌症治療剤を提供することができた。INDUSTRIAL APPLICABILITY According to the present invention, it is useful as a therapeutic agent for dermatomycosis, and in particular, by foot bathing an affected area affected by a fungus such as Trichophyton, a short-term treatment that is unthinkable with conventional treatment methods. Between and in a very good and effective way,
It was possible to provide a therapeutic agent for dermatomycosis capable of performing treatment for recovering an affected area to a clean state.
Claims (8)
性イオン界面活性剤と（Ｃ）非イオン性界面活性剤とか
らなることを特徴とする皮膚真菌症治療剤。1. A therapeutic agent for dermatomycosis, which comprises (A) a cationic surfactant, (B) a zwitterionic surfactant, and (C) a nonionic surfactant.
アンモニウム塩よりなる陽イオン性界面活性剤であるこ
とを特徴とする、請求項１に記載の皮膚真菌症治療剤。2. The therapeutic agent for dermatomycosis according to claim 1, wherein the cationic surfactant (A) is a cationic surfactant composed of a quaternary ammonium salt.
コニウムであることを特徴とする、請求項１または２に
記載の皮膚真菌症治療剤。3. The therapeutic agent for dermatomycosis according to claim 1 or 2, wherein the quaternary ammonium salt is benzalkonium chloride.
カルボン酸またはその塩よりなる両性イオン界面活性剤
であることを特徴とする、請求項１〜３いずれか一項に
記載の皮膚真菌症治療剤。4. The skin fungus according to any one of claims 1 to 3, wherein (B) the zwitterionic surfactant is a zwitterionic surfactant composed of aminocarboxylic acid or a salt thereof. Disease treatment agent.
アルキルジ（アミノエチル）グリシンまたはその塩であ
ることを特徴とする、請求項１〜４いずれか一項に記載
の皮膚真菌症治療剤。5. The therapeutic agent for dermatomycosis according to any one of claims 1 to 4, wherein the aminocarboxylic acid or its salt is a long-chain alkyldi (aminoethyl) glycine or its salt.
ル型非イオン性界面活性剤であることを特徴とする、請
求項１〜５いずれか一項に記載の皮膚真菌症治療剤。6. The therapeutic agent for dermatomycosis according to any one of claims 1 to 5, wherein the nonionic surfactant (C) is an ether type nonionic surfactant.
リオキシエチレンアルキルエーテルよりなる界面活性剤
であることを特徴とする、請求項１〜６いずれか一項に
記載の皮膚真菌症治療剤。7. The therapeutic agent for dermatomycosis according to claim 1, wherein the ether type nonionic surfactant is a surfactant made of polyoxyethylene alkyl ether. .
特徴とする、請求項１〜７のいずれか一項に記載の皮膚
真菌症治療剤。8. The therapeutic agent for dermatomycosis according to any one of claims 1 to 7, wherein the therapeutic agent for dermatomycosis is a liquid agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17159494A JPH0812572A (en) | 1994-07-01 | 1994-07-01 | Therapeutic agent for dermatomycosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17159494A JPH0812572A (en) | 1994-07-01 | 1994-07-01 | Therapeutic agent for dermatomycosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0812572A true JPH0812572A (en) | 1996-01-16 |
Family
ID=15926063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17159494A Pending JPH0812572A (en) | 1994-07-01 | 1994-07-01 | Therapeutic agent for dermatomycosis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0812572A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000010556A1 (en) * | 1998-08-19 | 2000-03-02 | Beiersdorf Ag | Use of quaternary nitrogen compounds for prophylaxis or treatment of superinfected atopic eczema |
| WO2000064429A1 (en) * | 1999-04-22 | 2000-11-02 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Pharmaceutical composition effective against pathological conditions caused by bacteria, viruses, fungi, yeasts and protozoa |
| EP1126012A1 (en) * | 2000-02-17 | 2001-08-22 | Bode Chemie GmbH & Co. | Cleaning and sanitizing systems for medical devices |
| EP1126013A1 (en) * | 2000-02-17 | 2001-08-22 | Bode Chemie GmbH & Co. | Cleaning composition for medical devices |
| JP2006335650A (en) * | 2005-05-31 | 2006-12-14 | Sanyo Chem Ind Ltd | Anti-trichophytial external preparation |
-
1994
- 1994-07-01 JP JP17159494A patent/JPH0812572A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000010556A1 (en) * | 1998-08-19 | 2000-03-02 | Beiersdorf Ag | Use of quaternary nitrogen compounds for prophylaxis or treatment of superinfected atopic eczema |
| WO2000064429A1 (en) * | 1999-04-22 | 2000-11-02 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Pharmaceutical composition effective against pathological conditions caused by bacteria, viruses, fungi, yeasts and protozoa |
| EP1126012A1 (en) * | 2000-02-17 | 2001-08-22 | Bode Chemie GmbH & Co. | Cleaning and sanitizing systems for medical devices |
| EP1126013A1 (en) * | 2000-02-17 | 2001-08-22 | Bode Chemie GmbH & Co. | Cleaning composition for medical devices |
| JP2006335650A (en) * | 2005-05-31 | 2006-12-14 | Sanyo Chem Ind Ltd | Anti-trichophytial external preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60020342T2 (en) | DEEP-PUNCHING ANTIMICROBIAL COMPOSITIONS | |
| CN1041989C (en) | Synergistic biocidal composition | |
| US5858383A (en) | Methods and compositions for topical treatment of ectoparasites | |
| RU2441644C2 (en) | Soft compositions for skin disinfection | |
| DK176254B1 (en) | Detergent composition containing hinokitol as antiseptic | |
| DE2906213C2 (en) | Cosmetic and therapeutic cleaning agent | |
| WO2022152164A1 (en) | Cleaning composition having bacteriostatic effect and preservative-free cleaning product | |
| US9855222B2 (en) | Topical sanitizer that includes avenanthramides | |
| US20190000737A1 (en) | Personal Care Compositions Comprising a 2-Pyridinol N-Oxide Material and an Iron Chelator | |
| JPS61243010A (en) | Cosmetic containing epsilon-polylysine and hydrochloride thereof as preservative and germicide incorporated therein | |
| US4184974A (en) | Liquid biocidal compositions comprising a mixture of silver ions and sodium pectate | |
| EP1786391B1 (en) | Composition for combating msra on hands comprising polyhexamethylenebiguanide | |
| DE69000182T2 (en) | CLEANING AGENT IN PARTICULAR NAFTIFIN AND / OR TERBINAFIN. | |
| JPH0812572A (en) | Therapeutic agent for dermatomycosis | |
| JPH05112795A (en) | Detergent composition | |
| EP1876225A1 (en) | Broad spectrum and skin friendly disinfecting composition | |
| JPH0625695A (en) | Detergent composition | |
| US20170246095A1 (en) | Topical sanitizer that includes avenanthramides | |
| JPH0672858A (en) | Detergent for body and hair of head | |
| JP3645287B2 (en) | Antidandruff agent | |
| JP2002332237A (en) | External preparation for skin | |
| CN111437208A (en) | Scalp hair cleansing composition, scalp care product, and scalp care method | |
| JPH06128587A (en) | Detergent composition | |
| WO2021009888A1 (en) | Pediculicide | |
| GB2275191A (en) | Use of tolnaftate and tolciclate in treatment of skin disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050517 |
|
| A02 | Decision of refusal |
Effective date: 20051011 Free format text: JAPANESE INTERMEDIATE CODE: A02 |